TRCT
CPHR

Tower Research Capital (TRC)’s Cipher Pharmaceuticals Inc. CPHR Stock Holding History

Tower Research Capital (TRC)’s Portfolio CPHR Stock Details CPHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,100
Closed -$8K – 4911
2016
Q3 		$8K Buy
2,100
+990
+89% +$4.51K ﹤0.01% 2281
2016
Q2 		$6K Buy
1,110
+814
+275% +$4.64K ﹤0.01% 3325
2016
Q1 		$1K Sell
296
-1,306
-82% -$5.74K ﹤0.01% 3955
2015
Q4 		$7K Buy
1,602
+269
+20% +$1.16K ﹤0.01% 2689
2015
Q3 		$5K Sell
1,333
-467
-26% -$3.25K ﹤0.01% 2874
2015
Q2 		$16K Buy
1,800
+265
+17% +$2.64K ﹤0.01% 2327
2015
Q1 		$14K Buy
1,535
+1,025
+201% +$12.9K ﹤0.01% 2555
2014
Q4 		$7K Buy
+510
New +$7.4K ﹤0.01% 2525

Other funds holding CPHR

GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
NEI
Northwest & Ethical Investments Toronto, Ontario, Canada $4.32B AUM 23.26% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Tower Research Capital (TRC)'s CPHR Position: Q4 2016 in Review

Tower Research Capital (TRC) sold out of Cipher Pharmaceuticals Inc. (CPHR) in Q4 2016, closing a stake of 2,100 shares — an estimated $8K sold.

Tower Research Capital (TRC) first reported a position in CPHR in Q4 2014 and held it in 8 quarters. The position peaked at $16K in Q2 2015. 3 funds tracked by Wall St. Rank hold CPHR as of Q4 2016.

  • Tower Research Capital (TRC) reported no remaining Cipher Pharmaceuticals Inc. position as of Q4 2016 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2,100 Cipher Pharmaceuticals Inc. shares in Q4 2016, an estimated $8K.
  • Tower Research Capital (TRC) first reported a position in Cipher Pharmaceuticals Inc. in Q4 2014 and held it in 8 quarters.
  • Tower Research Capital (TRC)'s Cipher Pharmaceuticals Inc. position peaked at $16K in Q2 2015.
  • 3 funds tracked by Wall St. Rank held Cipher Pharmaceuticals Inc. as of Q4 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2016, filed 3 Feb 2017.